MSN Laboratories Private Limited

		K&D Center	, Formulation Division
	MATERIAL SAFETY DATA SHEET		
Product Name	Erlotinib Tablets 25 mg, 100 mg and 150 mg/		
1 Toutet Name	Erlotinib 25 mg, 100 mg and 150 mg Film Coated Tablets]	Page No 1 of 4

1. Product Information

Product Name: Erlotinib Tablets 25 mg, 100 mg and 150 mg/

Erlotinib 25 mg, 100 mg and 150 mg Film Coated Tablets

2. Composition/Information on Ingredients

C.A.S. No:

: 183319-69-9

Molecular Formula

: C22H23N3O4.HCI

Molecular Weight

: 429.90

Chemical Name

: N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)4-quinazolinamine

3. Hazards Identification

Handling should only be performed by personnel trained and familiar with handling of potent active pharmaceutical ingredients Moderate to severe irritant to the skin and eyes.

4. First Aid Measures

Eye Contact: Check for and remove contact lenses and flush with copious amounts of water; assure adequate flushing by separating the eyelids with fingers; call a physician.

Skin Contact: flush with copious amounts of water; remove contaminated clothing and shoes; call a physician.

Ingestion: If swallowed, wash out mouth with copious amounts of water; call a physician.

Inhalation: If inhaled, remove to fresh air; if breathing is difficult, give oxygen; if breathing stops, give artificial respiration.

5. Emergency Overview

Major Health Hazards: No major health hazards are known.

6. Fire Fighting Measure	6.	Fire	Fighting	Measure
--------------------------	----	------	----------	---------

Suitable

Carbon dioxide, dry chemical powder. Water spray. Avoid spill into drains, surface

extinguishing media:

and groundwater and soil.

Special protective

Wear self-contained breathing apparatus and protective clothing to prevent contact

MSN Laboratories Private Limited R&D Center. Formulation Division

		Ray Center, Formula	ation Divisio
	MATERIAL SAFETY DATA SHEET		-
Product Name	Erlotinib Tablets 25 mg, 100 mg and 150 mg/		
1 Todact Name	Erlotinib 25 mg, 100 mg and 150 mg Film Coated Tablets	Page 1	No 2 of 4
			

equipment: with skin and eyes.

7. Accidental Release Measures

Personal precautions: Use personal protective equipment. Avoid dust formation. Avoid breathing dust. Ensure adequate ventilation. Evacuate personnel to safe areas.

Environmental precautions: Prevent further leakage or spillage. Do not let product enter into drains.

Methods and materials for containment and cleaning up: Pick up and arrange disposal without creating dust. Keep in suitable, closed containers for disposal

8. Handling and Storage

Precautions for safe handling:

Avoid formation of dust and aerosols. Provide appropriate exhaust ventilation at places where dust is formed. Normal measures for preventive fire protection.

Storage Conditions: Store as directed by product packaging.

9. Exposure Controls/Personal Protection

Personal protective equipment: Glasses, Gloves, Respirator, Particulate etc

Respiratory protection:

Where risk assessment shows air-purifying respirators are appropriate use a full-face particle respirator type N99 (US) or type P2 (EN 143) respirator cartridges as a backup to engineering controls. If the respirator is the sole means of protection, use a full-face supplied air respirator. Use respirators and components tested and approved under appropriate government standards such as NIOSH (US) or CEN (EU).

Hand protection: The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and the standard EN 374 derived from it. Handle with gloves.

Eye protection: Wear protective chemical safety goggles.

Skin and body protection:

Choose body protection according to the amount and concentration of the dangerous substance at the work place.

Hygiene measures: Avoid contact with skin, eyes and clothing. Wash hands before breaks and immediately after handling the product.



	<u> </u>	&D Center, Formulation Division
	MATERIAL SAFETY DATA SHEET	
Product Name	Erlotinib Tablets 25 mg, 100 mg and 150 mg/	·
1 Todatet Hame	Erlotinib 25 mg, 100 mg and 150 mg Film Coated Tablets	Page No 3 of 4

10. Physical and Chemical Properties

Appearance:

25 mg: White colored, round shaped, biconvex, film coated tablets, debossed with "E 25" on one side and plain on other side.

100 mg: White colored, round shaped, biconvex, film coated tablets, debossed with "E 100" on one side and plain on other side..

150 mg: White colored, round shaped, biconvex, film coated tablets, debossed with "E 150" on one side and plain on other side.

11. Stability and Reactivity

Stability: Stable under normal conditions of use.

Conditions to Avoid: Fine particles (such as dust and mists) may fuel fires/explosions.

Incompatible Materials: As a precautionary measure, keep away from strong oxidizers

Hazardous Decomposition Products: None known

12. Toxicological Information

- Acute toxicity:
- Lethal Dose Ld₅₀ Rat {Oral} : 2000 mg/kg.
- Skin corrosion/irritation:
- No data available.
- · Serious eye damage/eye irritation:
- No data available.
- Respiratory or skin sensitization:
- No data available.
- Carcinogenicity: Riociguat was non-carcinogenic.
- Mutagenicity: Riociguat is considered not to be genotoxic.
- Reproductive toxicology & Teratology: In rats, no effects on male and female fertility were seen with Riociguat
- Specific target organ toxicity single exposure: Not available
- · Specific target organ toxicity repeated exposure: No data available
- Aspiration hazard: No data available

MSN Laboratories Private Limited

***		R&D Center, Formulation Division
J i	MATERIAL SAFETY DATA SHEET	
Product Name	Erlotinib Tablets 25 mg, 100 mg and 150 mg/	
	Erlotinib 25 mg, 100 mg and 150 mg Film Coated Tablets	Page No 4 of 4
	· · · · · · · · · · · · · · · · · · ·	

Potential health effects:

• Inhalation: May be harmful if inhaled. May cause respiratory tract irritation.

Ingestion: May be harmful if swallowed

Skin: May be harmful if absorbed through skin. May cause skin irritation.

Eyes: May cause eye irritation.

Additional Information

RTECS: Not available

13. Ecological Information

Toxicity:

Avoid release into the environment.

Runoff from fire control or dilution water may cause pollution

Persistence and Degradability: No data available.

Bioaccumulative Potential

: No data available.

Mobility in Soil

: No data available.

Results of PBT and vPvB assessment: No data available.

Other adverse effects

: No data available.

14. Disposal Considerations

Dispose of in accordance with prevailing country, federal, state and local regulations.

15. Transport Information

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations

16. Regulatory Information

This safety data sheet complies with the requirements of Regulation (EC) No. 1272/2008.

17. Other Information

While the information herein is believed to be reliable, it is furnished without warranty of any kind. It shall be used only as a guide. We assume no liabilities from the use of this product or information contained herein.